Breaking News, Collaborations & Alliances

Sanyou and KangaBio Enter Antibody Drug Licensing Agreement

Will work together to contribute to the development of innovative prodrugs for immunotherapy.

Author Image

By: Charlie Sternberg

Associate Editor

Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. and Shanghai KangaBio Co., Ltd. have reached an antibody drug licensing agreement regarding a proprietary monoclonal antibody drug developed by Sanyou, which grants KangaBio an exclusive license to exploit the antibody for research, development, manufacturing and commercialization of immunotherapy products.   KangaBio is committed to developing innovative prodrugs and providing innovative medicine to address unmet clinical needs. Sanyou is a biolo...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters